Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss. Improving distant control of lung cancer is the most exciting potential benefit of combining ...
MedPage Today on MSN
Time of Day Matters for Immunochemotherapy in Lung Cancer
This is a "landmark study" for cancer immunotherapy and circadian medicine, researcher say ...
SurvivorNet on MSN
Could timing give your cancer treatment a boost? New study on the best time to receive immunotherapy & chemo for non-small cell lung cancer
A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...
INSIGHT-003 is evaluating eftilagimod alpha (efti) in combination with the anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) and doublet chemotherapy as first-line treatment for patients with advanced or ...
Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...
– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy ...
First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen in an earlier stage of cancer to ...
The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50 ...
Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results